Nuvation Bio
NUVB
105 hedge funds and large institutions have $1.32B invested in Nuvation Bio in 2021 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 48 increasing their positions, 26 reducing their positions, and 10 closing their positions.
199% more call options, than puts
Call options by funds: $371K | Put options by funds: $124K
85% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 26
70% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 10
7% more funds holding
Funds holding: 98 → 105 (+7)
1.87% more ownership
Funds ownership: 69.47% → 71.35% (+1.9%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
12% less capital invested
Capital invested by funds: $1.5B → $1.32B (-$184M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$49.6M |
| 2 |
State Street
Boston,
Massachusetts
|
+$12.2M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$6.88M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$6.15M |
| 5 |
JP Morgan Chase
New York
|
+$5.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$48.3M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$8M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$7.17M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.9M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.27M |
NUVB Hedge Fund Activity: Q4 2021 in Review
105 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Nuvation Bio (NUVB) for Q4 2021, worth a combined $1.32B — down 12% from $1.5B a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new NUVB positions and 10 closed out — a net gain of 7 holders — while 48 added to existing stakes and 26 trimmed.
The largest buyer was BlackRock, adding an estimated $49.6M. The largest seller was Omega Fund Management, cutting an estimated $48.3M.
- 105 institutional investors held Nuvation Bio (NUVB) as of Q4 2021, up from 98 in Q3 2021.
- Funds reported $1.32B of Nuvation Bio stock for Q4 2021, down 12% quarter-over-quarter.
- 17 funds opened new Nuvation Bio positions in Q4 2021 and 10 closed out, a net change of +7 holders.
- The largest Nuvation Bio buyer in Q4 2021 was BlackRock, an estimated $49.6M added.
- The largest Nuvation Bio seller in Q4 2021 was Omega Fund Management, an estimated $48.3M sold.
Based on aggregated 13F filings for Q4 2021.